Heat Biologics Presents Proprietary Allogeneic Cell Line Antigen Screening Algorithm And Systematic Analysis Of Combination Tumor Immunotherapy Preclinical Data At The 105th Annual Meeting Of American Association for Cancer Research
4/10/2014 10:29:11 AM
CHAPEL HILL, NC--(Marketwired - Apr 9, 2014) - Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company") (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that the Company presented results of two preclinical ImPACT Therapy based research studies at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held April 5-9, 2014 in San Diego.
Help employers find you! Check out all the jobs and post your resume.
comments powered by